IBD says BABA is basing. Question is will it move up or down after it breaks out of the base. Discouraging price movement. I wonder if its fear of a big selloff in March when the big lock-up period expires, then in Sept. Are fund mgrs staying out until this is past? I'd had to trade sideways while the general market moves upward.
This was a small expiration. March and September will be more of a concern. That being said, what fund manager doesn't want to have a position in BABA next year???
I want more than a buyback, I want an explanation. Someone in management has been asleep at the wheel to let this ABBV deal go on right under their noses!
China Mobile is just getting on board. I think iphone sales are just getting fired up. Maybe this new competitor that is using android stole some of the thunder in China but I still feel we will see robust sales.
And now we are forced to buy inferior drugs! When does it end?
Thanks Express Scripts! Sell this POS!
Regardless the babies are being thrown out with the bath water here.
You can blame some shortfall on strong U.S. dollar but same store sales in domestic business means they are losing to competition. Wendy's, Burger King, Hardee's are taking market share. The dividend is their only saving grace or it'd be down 20%.
Yes you are right, it looks like around 12/21 is anticipated date. I got this from the Fool article: ..We should have that soon when AbbVie (NYSE: ABBV ) gets its hepatitis C drugs approved by the FDA in December. Enanta Pharmaceuticals will share in the wealth, having helped develop one of the drugs in the cocktail. The PDUFA date for the drugs is Dec. 21, but an approval could come early, especially if FDA reviewers want to clear their desks before the holidays.
While it's always possible the drugs might not get approved, it's highly unlikely. The cocktail is able to rid a vast majority of patients of their hepatitis C virus and appears safe enough to gain approval. The drugs were recently given a positive opinion from the European Committee for Medicinal Products for Human Use. Abbvie just has to wait on the rubber stamp approval from the European Commission before it can launch the drugs, which will go by Viekirax and Exviera, in Europe.
Once approved, Viekirax and Exviera will compete with Gilead Sciences' (NASDAQ: GILD ) Harvoni. As a single pill taken once a day, Harvoni has the clear advantage over Abbvie's regimen, which requires two pills, one of which has to be taken twice a day. AbbVie might be able to capture some of the market share if it discounts its combination enough to get health insurers to make its cocktail the preferred (or perhaps only) hepatitis C drugs covered by the insurance plan.
I'm hoping this won't retreat! Keeping my fingers crossed! 105 now!